For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on June 29th, 2022 | 12:18 CEST
Buy or sell? Nel, Zalando, Aspermont under analyst review
After the heavy losses of the past months, a countermovement seems to be starting at the moment. Whether this will turn into a real summer rally remains to be seen. Buy or sell is the question. Analysts see a price potential of over 50% for Nel ASA. Even though competition from China and India is increasing. Aspermont also appears attractive at the current price level. The latest quarterly figures were positive, and the positioning of the small-cap in the booming commodities sector is promising. At Zalando, analysts react to the profit warning, and the price targets are significantly reduced. Nevertheless, some advise buying the online fashion retailer, but not everyone.
Read
Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST
Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?
Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.
Read
Commented by Fabian Lorenz on June 22nd, 2022 | 14:39 CEST
Golden times for Nel and Varta? Tension is rising at First Hydrogen
The prices for oil, gas & Co. remain at a high level this week, not least because Russia has reduced gas supplies to Europe. In Germany, Economics Minister Robert Habeck is working at full speed on emergency plans for the winter and is calling for energy savings. In the long term, there will be no way around renewable energies. Analysts expect golden times for companies like Nel ASA and Varta. But smaller innovative companies like hydrogen pure-play First Hydrogen are also interesting. That is because analysts expect demand for hydrogen to outstrip supply massively. In the battery sector, Goldman Sachs recommends buying the Varta share. The MDAX group's sales are expected to more than double in the coming years, thanks to electromobility. The annual general meeting was held yesterday.
Read
Commented by Fabian Lorenz on June 16th, 2022 | 13:37 CEST
Insider alert at Varta, recommendation for Plug Power, Altech Advanced Materials with news
The energy and mobility turnaround is in full swing. Nevertheless, shares from this sector have also taken a beating in the stock market quake of recent weeks. Today we look at companies from this future market with current news. Alarm bells are ringing at Varta. A few days before the annual general meeting, an insider sells shares and generates an amount in the double-digit millions. At the same time, important news is imminent. Plug Power has recently seen a positive news flow. Nevertheless, the share has lost considerable ground - but according to an analyst, triple-digit price gains await. Such gains do not seem unrealistic for Altech Advanced Materials either if battery technology can be revolutionized.
Read
Commented by Fabian Lorenz on June 15th, 2022 | 13:47 CEST
Big bang for BYD and Rheinmetall: wallstreet:online insider buying
Investors need strong nerves at the moment. Stock markets worldwide are shaking, and it is not just technology stocks that are plummeting. But, there are also opportunities. It is important to check the portfolio and bet on the right shares. Rheinmetall seems to be unstoppable at the moment. Goldman Sachs sees significant upside potential, and the new Panther tank is causing a stir. Analysts are also optimistic about BYD, and speculation about a deal with Tesla is driving the share to a new all-time high in euro terms. wallstreet:online is a long way from that. But the business is going, insiders are buying shares, and analysts advise to buy.
Read
Commented by Fabian Lorenz on June 9th, 2022 | 11:19 CEST
Shares of Nel ASA, BP, BASF and Saturn Oil + Gas: Goldman bullish on oil price
Good news for oil producers such as BP, ExxonMobil and Saturn Oil & Gas: Goldman Sachs has raised its oil price forecasts and expects prices to remain high. The price target for Brent crude was raised from USD 125 to USD 140 per barrel. The reasons given for this are unresolved structural bottlenecks. The oil giant ExxonMobil shot up to a new all-time high in the wake of the news. For Saturn Oil & Gas, a takeover has come at the right time. The Canadian producer wants to double its production again. Nel is also likely to benefit, as the high prices for fossil energies are making it easier to switch to renewables. For BASF, however, the Goldman forecast is bad news, but analysts see considerable upside potential.
Read
Commented by Fabian Lorenz on June 8th, 2022 | 13:50 CEST
Shares: Plug Power and BYD with exclamation points! Patience is needed at Nevada Copper
Hydrogen or battery, which is better? This question is often asked. The answer is simple: both technologies will play an essential role in the energy and mobility revolution. While batteries seem to be gaining ground in the passenger car sector, hydrogen has numerous other potential applications, such as commercial vehicles and ships. Plug Power and BYD put exclamation points on incoming orders and vehicle sales. At the beginning of the value chain are commodity companies like Nevada Copper, which has now suffered a setback on its way to becoming a copper producer. However, the price slide could also represent an opportunity for investors.
Read
Commented by Fabian Lorenz on June 2nd, 2022 | 10:38 CEST
Alibaba, JinkoSolar and Hong Lai Huat: Stocks for the stimulus package
Asian stocks have been under pressure in recent months due to the Chinese government's strict Zero-COVID strategy with hard lockdowns like in the economic hub of Shanghai. Now they could benefit from easing and a stimulus package. In order to achieve the GDP growth target of 5.5% in 2022, the government in Beijing has put together an economic stimulus package. With 33 measures, private consumption - including the purchase of cars and household appliances - is to be boosted and investments in major projects promoted. It is not only Chinese stocks such as Alibaba and JinkoSolar that should benefit from this. The real estate sector in the entire Asian region should also breathe a sigh of relief and, with it, the Hong Lai Huat share.
Read
Commented by Fabian Lorenz on June 1st, 2022 | 13:44 CEST
Rain of money for BioNTech shareholders: What are Nordex and Meta Materials doing?
BioNTech shareholders are in for a windfall. A dividend of EUR 2 per share is to be approved at today's Annual General Meeting. Also on the agenda is a share buyback program with a volume of up to USD 1.5 billion. In addition, analysts at Goldman Sachs have commented positively on the German biotech champion. Meta Materials shareholders are still a long way from a dividend. But the hot stock has announced exciting details about its fight against stroke. At Nordex, by contrast, supply chain problems, plant closures and cyberattacks dominate the headlines. But analysts see the light at the end of the tunnel - and rightly so?
Read
Commented by Fabian Lorenz on May 26th, 2022 | 11:07 CEST
Nel ASA and Siemens Energy - buy or underweight? dynaCERT with sales partner
It is undisputed that the future belongs to renewable energies. New subsidy programs are passed almost weekly - especially in Europe. However, it is unclear whether now is the time to enter the market. Buy, or wait and see? Among other things, analysts do not agree on Nel ASA. After weak figures, JPMorgan has reduced the price target for the shares of the hydrogen specialist. And at Siemens Energy, too, opinions are divided. High inventory levels are a cause for concern. At the hydrogen company dynaCert, following personnel changes, there are again positive headlines due to a sales partnership and the hope for a share price recovery. Last week, the dynaCert CEO expressed confidence at an investor conference.
Read